Cureus
. 2021 Nov 26;13(11):e19919.
doi: 10.7759/cureus.19919. eCollection 2021 Nov.
Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
Mani Maheshwari 1 , Hemanthkumar Athiraman 1
Affiliations
- PMID: 34956798
- PMCID: PMC8675592
- DOI: 10.7759/cureus.19919
Abstract
Remdesivir is an antiviral that inhibits RNA-dependent RNA polymerases of coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a cornerstone of therapy for hospitalized patients with coronavirus disease 2019 (COVID-19), especially those worsening from a respiratory standpoint despite being started on antibiotics, dexamethasone, zinc, and vitamin C. This is a case report describing two COVID-19-positive patients with bradycardia after starting remdesivir. Once remdesivir was discontinued, one patient corrected to normal sinus rhythm, and the other continued with persistent bradycardia.
Keywords: adult hospital medicine; arrythymia; covid-19; drug induced bradycardia; remdesivir.